Last10K.com

Sangui Biotech International Inc (SGBI) SEC Filing 10-K Annual report for the fiscal year ending Sunday, June 30, 2019

Sangui Biotech International Inc

CIK: 1104280 Ticker: SGBI
Document and Entity Information - USD ($)
12 Months Ended
Jun. 30, 2019
Sep. 28, 2019
Dec. 31, 2018
Details   
Registrant CIK0001104280  
Fiscal Year End--06-30  
Registrant NameSANGUI BIOTECH INTERNATIONAL INC  
SEC Form10-K  
Period End dateJun. 30, 2019  
Tax Identification Number (TIN)84-1330732  
Number of common stock shares outstanding 201,479,842 
Public Float  $ 3,527,851
Filer CategoryNon-accelerated Filer  
Current with reportingYes  
Interactive Data CurrentYes  
Voluntary filerNo  
Well-known Seasoned IssuerNo  
Shell Companyfalse  
Small Businesstrue  
Emerging Growth Companyfalse  
Document Annual Reporttrue  
Entity File Number0-21271  
Entity Address, State or ProvinceCO  
Entity Incorporation, State or Country CodeCO  
Entity Address, Address Line OneNeuer Wall 54  
Entity Address, City or TownHamburg  
Entity Address, CountryDE  
Entity Address, Postal Zip Code20354  
Country Region49  
City Area Code40  
Local Phone Number6093120  
Document Transition Reportfalse  
Amendment Flagfalse  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Sangui Biotech International Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Sangui Biotech International Inc.

Continue

Assess how Sangui Biotech International Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Sangui Biotech International Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Income (Loss)
Consolidated Statements Of Stockholders' Equity (Deficit)
Note 1 - Organization And Summary Of Significant Accounting Policies
Note 1 - Organization And Summary Of Significant Accounting Policies (Policies)
Note 1 - Organization And Summary Of Significant Accounting Policies (Tables)
Note 1 - Organization And Summary Of Significant Accounting Policies: Basic And Diluted Loss Per Common Share (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Concentration Of Credit Risk (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Foreign Currency Translation (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Foreign Currency Translation: Schedule Of Foreign Currency Rates (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Going Concern (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Non-Controlling Interests (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Note 9 - Note Payable (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Principles Of Consolidation (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Property And Equipment (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Research And Development (Details)
Note 1 - Organization And Summary Of Significant Accounting Policies: Trade Accounts Receivable (Details)
Note 10 - Subsequent Events
Note 10 - Subsequent Events (Details)
Note 2 - License Agreement &Amp; Investment In Joint Venture
Note 2 - License Agreement &Amp; Investment In Joint Venture (Details)
Note 3 - Property And Equipment
Note 3 - Property And Equipment (Details)
Note 3 - Property And Equipment (Tables)
Note 3 - Property And Equipment: Schedule Of Property And Equipment (Details)
Note 4 - Related Party Transactions
Note 4 - Related Party Transactions (Details)
Note 5 - Stockholders' Equity
Note 5 - Stockholders' Equity (Details)
Note 6 - Income Tax Provision
Note 6 - Income Tax Provision (Details)
Note 6 - Income Tax Provision (Tables)
Note 6 - Income Tax Provision: Schedule Of Income Tax Provision (Details)
Note 7 - Commitments And Contingencies
Note 7 - Commitments And Contingencies (Details)
Note 8 - Stock-Based Compensation
Note 8 - Stock-Based Compensation (Details)
Note 9 - Note Payable
Note 9 - Note Payable (Details)
Ticker: SGBI
CIK: 1104280
Form Type: 10-K Annual Report
Accession Number: 0001445866-19-001219
Submitted to the SEC: Tue Oct 08 2019 4:29:09 PM EST
Accepted by the SEC: Tue Oct 08 2019
Period: Sunday, June 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/sgbi/0001445866-19-001219.htm